Can people with ETO fusion genes take Midostaurin?

Midostaurin is a multi-target tyrosine kinase inhibitor mainly used to treat FLT3 mutant acute myeloid leukemia (AML) and systemic mastocytosis and other diseases. It interferes with the proliferation and survival of tumor cells by inhibiting kinase activity in multiple signaling pathways. However, in actual clinical practice, some AML patients carry different genetic abnormalities, such as ETO fusion genes ( That is, the RUNX1-RUNX1T1 fusion gene), which is more common in the M2 type of acute myeloid leukemia. Then, whether patients carrying such fusion genes can use midostaurin needs to be analyzed based on the characteristics of the disease.

First of all, it needs to be clear that midostaurin is mainly targeted at FLT3 mutation-positive AML patients, especially those with FLT3-ITD or FLT3-TKD mutations. In the presence of these mutations, tumor cells rely on the FLT3 signaling pathway to continue to proliferate, and midostaurin can effectively inhibit this pathway and delay disease progression. The ETO fusion gene is not equivalent to the FLT3 mutation. It represents another molecular abnormality that is not directly related to the main target of midostaurin. Therefore, the use of midostaurin is generally not recommended for AML patients who simply carry the ETO fusion gene but do not have the FLT3 mutation, because its therapeutic mechanism is not suitable for these patients.

However, in reality, there are also situations where ETO fusion genes coexist with FLT3 mutations. Although uncommon, in such patients, midostaurin may still be considered if a positive FLT3 mutation is detected, even if the ETO fusion gene is present. In fact, in the standardized treatment process, as long asIf FLT3mutation is positive, midostaurin combined with chemotherapy can be used as a first-line treatment option, and there is no need to exclude its use due to the presence of the ETO fusion gene. The key is to clarify the mutation status of FLT3 through molecular diagnosis, so as to develop a personalized medication plan.

In short, whether midostaurin can be used depends critically on whether there is a FLT3 mutation rather than whether it carries the ETO fusion gene. Pure ETO positivity does not constitute an indication for the use of midostaurin, but if the patient is combined with FLT3 mutation, midostaurin is still an effective treatment option. It is recommended that patients undergo detailed genetic testing before treatment so that doctors can decide whether to introduce midostaurin or other targeted treatment options based on the specific mutation background to ensure scientific and targeted treatment.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html